Wave Life Sciences Ltd. (WVE) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.15

From 52W high−85.12%

Volume1.86M

Market cap$625.21M

P/E (TTM)—

P/S (TTM)9.6x

Div yield—

Key dataOct 19, 2026

Open

$3.15

From 52W high

−85.12%

Volume

1.86M

Market cap

$625.21M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.9x

P/E (TTM)

—

RSI (14)

26.9

MomentumView details →

1D Return

+1.28%

YTD Return

−81.28%

SummaryUpdated Jun 1, 2026

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.

Ask drillr about Wave Life Sciences Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.9x

EV/Sales

2.7x

P/S (TTM)

9.6x

P/B (TTM)

1.4x

ProfitabilityView details →

Gross Margin

96.54%

Net Margin

−309.73%

EBITDA Margin

−302.09%

ROE (TTM)

−44.64%

ROA (TTM)

−36.26%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

−30.42%

EPS YoY

−22.47%

FCF YoY

+6.93%

Revenue CAGR 3Y

+127.08%

EPS CAGR 3Y

−72.86%

EBITDA YoY

−52.35%

MomentumView details →

1D Return

+1.28%

YTD Return

−81.28%

1Y Return

−59.26%

RSI (14)

26.9

vs 50D SMA

−27.83%

vs 200D SMA

−59.90%

Capital & dividendView details →

Debt/Equity

0.10x

Current Ratio

9.99x

Quick Ratio

9.99x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.34

EPS Surprise

−13.43%

Beats (12Q)

6/12

Next Q EPS Est

−$0.33

Avg Surprise (4Q)

8.51%

Rev Surprise

−69.50%

Financials snapshotView financials →

Revenue (TTM)

65.37M

Net Income (TTM)

−202.47M

Op. CF (TTM)

−184.68M

Next earningsNov 9, 2026 →

Latest newsMore news →

Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.16h ago

The FDA provided feedback supporting a registrational pathway for Wave Life Sciences' WVE-006 RNA editing therapy in alpha-1 antitrypsin deficiency, following which Wave plans a single two-year registrational trial with a one-year interim analysis for potential accelerated approval.19d ago

Similar companies

Candel Therapeutics, Inc.CADL Sagimet Biosciences Inc.SGMT Olema Pharmaceuticals, Inc.OLMA Avalo Therapeutics, Inc.AVTX Nuvectis Pharma, Inc.NVCT Attovia Therapeutics, Inc.ATTO Find similar companies →

Latest newsMore news →

Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.16h ago The FDA provided feedback supporting a registrational pathway for Wave Life Sciences' WVE-006 RNA editing therapy in alpha-1 antitrypsin deficiency, following which Wave plans a single two-year registrational trial with a one-year interim analysis for potential accelerated approval.19d ago